Mahesh Narayanan, Chief Operating Officer, will present at PA Bio's annual Life Sciences Future conference on Wednesday, October 26 in Philadelphia. ImMAGE's presentation will focus on preliminary results from their first round of animal trials. The animal trials follow completion of positive in-vitro trials that targeted a specific protein, MAGE A, to find a better treatment for TNBC.
ImMAGE has also been selected to participate in YEi Start in France, an accelerator designed to help entrepreneurs grow their business in France and Europe. ImMAGE will complete a one-week immersion in France on December 4-9 that will connect the company to extensive resources and business networks in Europe.
About ImMAGE Biotherapeutics
ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-milestones-and-recognition-for-immage-biotherapeutics-300326559.html
SOURCE ImMAGE Biotherapeutics Corp.